Macupatide Monotherapy and in Combination With Eloralintide in Japanese Participants With Obesity or Overweight

Phase 1, randomised trial of macupatide in obesity (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at 25 weeks. Planned start Oct 2026; status: not yet recruiting.